Relationship between SARS-CoV-2 infection and intensive care unit (ICU)-acquired candidemia in critically ill medical patients: a multicenter prospective cohort study
Authors' conclusion
In this large multicenter cohort of ICU patients, although remaining low, the rate of ICAC was higher among COVID-19 patients.
Study context
- Population
- Adults hospitalised ≥48 h for a medical reason in ICUs of the French REA-REZO network, January 2020 to January 2023
- Participants
- 55,268 adults · 101 ICUs
- Exposure
- SARS-CoV-2 positive vs negative patients
- COVID-19n = 13,472
- Non-COVID-19n = 41,796reference
- Outcome
- ICU-acquired candidemia (ICAC) rate
Methodological detailsmulticentre, propensity-score matched, surveillance network
- Multicentre
- Propensity-score matched
- Surveillance network
Main finding
As reported in the abstract
ICAC rate
P = 0.004
Observational data: associations, not effects.
Further findings
ICAC rate, overall population
P < 0.001
Per 1000 patients-days
| Outcome | COVID-19 | Non-COVID-19 | IRR (95% CI) | P value | |
|---|---|---|---|---|---|
| ICAC incidence rate | 0.51 | 0.32 | 1.58 (1.08–2.35) | P = 0.018 | |
| 0.512Incidence rate ratio (log scale) |
| Outcome | P value |
|---|---|
| ICU mortality, patients with vs without ICAC | P < 0.001 |
- ICU mortality, patients with vs without ICAC: ICAC 49.6%
- ICU mortality, patients with vs without ICAC: No ICAC 20.2%
Original publication
Relationship between SARS-CoV-2 infection and ICU-acquired candidemia in critically ill medical patients: a multicenter prospective cohort study. Crit Care. Published 27 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →